On March 27, 2026, the U.S. District Court for the District of Delaware preserved the jury’s willful infringement verdict against Alcon’s Hydrus Microstent across U.S. Patents 8,287,482; 9,370,443; and 11,389,328. The order awards $34.0 million in past damages—$5.5 million in lost profits and $28.5 million in royalty damages—plus pre- and post-judgment interest and supplemental damages to be calculated. An ongoing royalty of 10% of Hydrus revenue applies from entry of final judgment through November 10, 2028, the expiration of the last asserted patent. A final judgment is expected in the coming months after Alcon provides supplemental financial data to calculate supplemental damages and pre-judgment interest; the final judgment is subject to appeal by Alcon. No monetary damages will be recovered until Alcon exhausts its appeal rights or the appeal period lapses. Alcon filed ex parte reexamination petitions at the USPTO in June 2025 challenging the asserted claims; adverse, final outcomes ahead of a final litigation judgment could negatively affect recovery. The USPTO denied Alcon’s inter partes review petitions on two of the asserted patents in March 2023. Sight Sciences expects to record a $5.4 million success fee to operating expenses payable to Cooley LLP, which it plans to exclude from non-GAAP adjusted operating expenses.